Bobak Azamian Sells 10,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Key Points

• CEO Bobak Azamian sold 10,000 Tarsus Pharmaceuticals shares at an average price of $90.56, generating $905,600 under a pre-arranged Rule 10b5-1 trading plan. He continues to own 827,991 shares, worth approximately $75.0 million.
• TARS shares fell 5.1% to $82.77, despite the stock remaining near its one-year high of $91.53. The company reported a quarterly loss of $0.43 per share, missing estimates, while revenue of $173.91 million exceeded forecasts.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $92.57. Institutional investors own approximately 90.01% of the company.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,000 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $90.56, for a total transaction of $905,600.00. Following the transaction, the chief executive officer directly owned 827,991 shares of the company's stock, valued at approximately $74,982,864.96. This represents a 1.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Trading Down 5.1%

Shares of NASDAQ TARS traded down $4.45 during trading on Wednesday, hitting $82.77. 556,805 shares of the company traded hands, compared to its average volume of 755,010. The firm has a market capitalization of $3.63 billion, a P/E ratio of -75.94 and a beta of 0.54. The company has a quick ratio of 3.17, a current ratio of 3.20 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $67.09 and a 200-day moving average price of $66.33. Tarsus Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $91.53.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The firm had revenue of $173.91 million during the quarter, compared to analyst estimates of $169.65 million. On average, equities analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TARS shares. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. HC Wainwright restated a "buy" rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Mizuho cut their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Finally, Guggenheim reduced their target price on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $92.57.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its position in shares of Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company's stock worth $35,000 after acquiring an additional 291 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock worth $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank increased its stake in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company's stock valued at $70,000 after purchasing an additional 705 shares during the period. Truvestments Capital LLC raised its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company's stock valued at $74,000 after buying an additional 468 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $103,000. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.